This trial is !
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Endometrial Cancer
and you are
over 18
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

You are being asked to take part in this study because you have endometrial hyperplasia (a pre-cancerous growth of the lining of the uterus) and/or early-stage endometrial cancer. The goal of this clinical research study is to learn if the Mirena intrauterine device (levonorgestrel IUD), alone or in combination with everolimus, is effective for the treatment of endometrial hyperplasia and/or early-stage endometrial cancer. This is an investigational study. The levonorgestrel IUD is commercially available and FDA approved as a form of birth control. The use of the IUD itself to treat endometrial cancer is investigational. Everolimus is FDA approved and commercially available to treat kidney, breast, and pancreatic cancers. The combination of everolimus and the levonorgestrel IUD in this study to treat endometrial cancer is investigational. Up to 270 patients will be enrolled in this study. Up to 250 will take part at MD Anderson and up to 20 will take part at the Harris Health System.

Provided treatments

  • Device: Levonorgestrel Intrauterine Device (LIUD)
  • Drug: Everolimus
  • Behavioral: Questionnaire
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02397083. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 270 volunteers for the current phase.
Official trial title:
Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer